Trial Profile
A phase II trial of CHOP-14 with Mogamulizumab for untreated elderly patients with CCR4 positive adult T-cell leukemia/lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2023
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary) ; Cyclophosphamide; Daunorubicin; Prednisolone; Vincristine
- Indications Adult T-cell leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms Moga-CHOP-14
- 06 Jun 2023 Primary endpoint (1 year progression free survival) has been met, according to a results presented at the 59th Annual Meeting of the American Society of Clinical.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical .
- 22 Aug 2022 Planned End Date changed from 31 Oct 2021 to 31 Oct 2025.